{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:20Z","timestamp":1793398220284,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Talent Program of Ganzhou Sci-Tech and Medical Joint Program","award":["2025YLCE0054"],"award-info":[{"award-number":["2025YLCE0054"]}]},{"name":"Regional Programs of the National Natural Science Foundation of China","award":["82560474"],"award-info":[{"award-number":["82560474"]}]},{"name":"Regional Programs of the National Natural Science Foundation of China","award":["82560461"],"award-info":[{"award-number":["82560461"]}]},{"name":"Regional Programs of the National Natural Science Foundation of China","award":["82360507"],"award-info":[{"award-number":["82360507"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07885-w","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:17:13Z","timestamp":1771989433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fecal microbiota transplantation for advanced non-small cell lung cancer with secondary PD-1 resistance efficacy prognostic factors and microbiome diversity analysis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4446-7775","authenticated-orcid":false,"given":"Hongxiang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"7885_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"7885_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095\u2013103.","journal-title":"J Clin Oncol"},{"key":"7885_CR3","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589\u201397.","journal-title":"J Clin Oncol"},{"key":"7885_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut Microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97\u2013103.","journal-title":"Science"},{"key":"7885_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut Microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137.","journal-title":"Science"},{"key":"7885_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, et al. The commensal Microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104\u20138.","journal-title":"Science"},{"key":"7885_CR7","doi-asserted-by":"publisher","first-page":"808101","DOI":"10.3389\/fimmu.2022.808101","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lu L, He Z, et al. C-Reactive protein levels predict responses to PD-1 inhibitors in hepatocellular carcinoma patients. Front Immunol. 2022;13:808101.","journal-title":"Front Immunol"},{"key":"7885_CR8","doi-asserted-by":"crossref","unstructured":"Zhang Z, Mocanu V, Cai C, et al. Impact of fecal microbiota transplantation on obesity and metabolic Syndrome-A systematic review. Nutrients. 2019;11.","DOI":"10.3390\/nu11102291"},{"key":"7885_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/2326-6066.CIR-20-0196","volume":"8","author":"T Hakozaki","year":"2020","unstructured":"Hakozaki T, Richard C, Elkrief A, et al. The gut Microbiome associates with immune checkpoint Inhibition outcomes in patients with advanced Non-Small cell lung cancer. Cancer Immunol Res. 2020;8:1243\u201350.","journal-title":"Cancer Immunol Res"},{"key":"7885_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin Y, Dong H, Xia L, et al. The diversity of gut Microbiome is associated with favorable responses to Anti-Programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019;14:1378\u201389.","journal-title":"J Thorac Oncol"},{"key":"7885_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 Blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28:315\u201324.","journal-title":"Nat Med"},{"key":"7885_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084\u20139.","journal-title":"Science"},{"key":"7885_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602\u20139.","journal-title":"Science"},{"key":"7885_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595\u2013602.","journal-title":"Science"},{"key":"7885_CR15","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","volume":"66","author":"W Zhao","year":"2023","unstructured":"Zhao W, Lei J, Ke S, et al. Fecal microbiota transplantation plus Tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). EClinicalMedicine. 2023;66:102315.","journal-title":"EClinicalMedicine"},{"key":"7885_CR16","doi-asserted-by":"crossref","unstructured":"Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020; 8.","DOI":"10.1136\/jitc-2019-000398"},{"key":"7885_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cmet.2017.09.008","volume":"26","author":"RS Kootte","year":"2017","unstructured":"Kootte RS, Levin E, Saloj\u00e4rvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611\u2013e619616.","journal-title":"Cell Metab"},{"key":"7885_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","volume":"15","author":"Y Lu","year":"2022","unstructured":"Lu Y, Yuan X, Wang M, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol. 2022;15:47.","journal-title":"J Hematol Oncol"},{"key":"7885_CR19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","volume":"32","author":"Y Kim","year":"2024","unstructured":"Kim Y, Kim G, Kim S, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe. 2024;32:1380\u2013e13931389.","journal-title":"Cell Host Microbe"},{"key":"7885_CR20","doi-asserted-by":"crossref","unstructured":"Hadi DK, Baines KJ, Jabbarizadeh B, et al. Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the mimic phase 1 trial. J Immunother Cancer. 2025;13.","DOI":"10.1136\/jitc-2025-012659"},{"key":"7885_CR21","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B, Lenehan JG, Miller WH Jr., et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023;29:2121\u201332.","journal-title":"Nat Med"},{"key":"7885_CR22","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1038\/s41598-018-24342-x","volume":"8","author":"Q Le Bastard","year":"2018","unstructured":"Le Bastard Q, Ward T, Sidiropoulos D, et al. Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice. Sci Rep. 2018;8:6219.","journal-title":"Sci Rep"},{"key":"7885_CR23","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.21873\/anticanres.14182","volume":"40","author":"M Svaton","year":"2020","unstructured":"Svaton M, Zemanova M, Zemanova P, et al. Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in Non-small cell lung cancer. Anticancer Res. 2020;40:2209\u201317.","journal-title":"Anticancer Res"},{"key":"7885_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00280-022-04416-4","volume":"89","author":"F Nelli","year":"2022","unstructured":"Nelli F, Virtuoso A, Berrios JRG, et al. Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study. Cancer Chemother Pharmacol. 2022;89:529\u201337.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7885_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/1750743X.2025.2491300","volume":"17","author":"M Shibano","year":"2025","unstructured":"Shibano M, Takahashi M, Nakatsukasa H, et al. Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer. Immunotherapy. 2025;17:331\u20138.","journal-title":"Immunotherapy"},{"key":"7885_CR26","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1038\/s41598-024-53158-1","volume":"14","author":"K Iida","year":"2024","unstructured":"Iida K, Naiki T, Etani T, et al. Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma. Sci Rep. 2024;14:2520.","journal-title":"Sci Rep"},{"key":"7885_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1248\/bpb.b21-00939","volume":"45","author":"Y Kunimitsu","year":"2022","unstructured":"Kunimitsu Y, Morio K, Hirata S, et al. Effects of proton pump inhibitors on survival outcomes in patients with metastatic or unresectable urothelial carcinoma treated with pembrolizumab. Biol Pharm Bull. 2022;45:590\u20135.","journal-title":"Biol Pharm Bull"},{"key":"7885_CR28","doi-asserted-by":"publisher","first-page":"716317","DOI":"10.3389\/fimmu.2021.716317","volume":"12","author":"Q Giordan","year":"2021","unstructured":"Giordan Q, Salleron J, Vallance C, et al. Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of Anti-PD-1 immune checkpoint inhibitors. Front Immunol. 2021;12:716317.","journal-title":"Front Immunol"},{"key":"7885_CR29","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","volume":"184","author":"KC Lam","year":"2021","unstructured":"Lam KC, Araya RE, Huang A, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021;184:5338\u2013e53565321.","journal-title":"Cell"},{"key":"7885_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06026-3","volume":"617","author":"JS Park","year":"2023","unstructured":"Park JS, Gazzaniga FS, Wu M, et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023;617:377\u201385.","journal-title":"Nature"},{"key":"7885_CR31","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1136\/gutjnl-2023-330291","volume":"72","author":"X Kang","year":"2023","unstructured":"Kang X, Liu C, Ding Y, et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. Gut. 2023;72:2112\u201322.","journal-title":"Gut"},{"key":"7885_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1172\/JCI124332","volume":"130","author":"M Uribe-Herranz","year":"2020","unstructured":"Uribe-Herranz M, Rafail S, Beghi S, et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Invest. 2020;130:466\u201379.","journal-title":"J Clin Invest"},{"key":"7885_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/19490976.2015.1056973","volume":"6","author":"KM Telesford","year":"2015","unstructured":"Telesford KM, Yan W, Ochoa-Reparaz J, et al. A commensal symbiotic factor derived from bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg function. Gut Microbes. 2015;6:234\u201342.","journal-title":"Gut Microbes"},{"key":"7885_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41392-025-02226-7","volume":"10","author":"M Cao","year":"2025","unstructured":"Cao M, Deng Y, Hao Q, et al. Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment. Signal Transduct Target Ther. 2025;10:140.","journal-title":"Signal Transduct Target Ther"},{"key":"7885_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cncr.34565","volume":"129","author":"T Salous","year":"2023","unstructured":"Salous T, Shukla NA, Althouse SK, et al. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: big ten cancer research consortium BTCRC-LUN15-029. Cancer. 2023;129:264\u201371.","journal-title":"Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07885-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:02:01Z","timestamp":1774969321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07885-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7885"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07885-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical tissue acquisition procedure of this study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (Approval No. IIT2021092.) and was registered with the National Health Security Information Platform and Medical Research Information System of China, with the registration number MR-36-22-010054.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"447"}}